Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Affimed's fully human anti-thrombosis antibody shows in vivo efficacy with reduced side effects

07 Dec 2006 - Affimed Therapeutics AG announced that preclinical proof of concept has been established for its anti-thrombosis product candidate. According to the company, Affimed's fully human antibody predominantly binds to the activated form of a receptor (GPIIb/IIIa) that plays a major role in the formation of blood clots.
 
The preclinical studies, conducted at the Dept. Cardiology and Dept. Clinical Pharmacology of Freiburg University, Germany and at the Baker Heart Research Institute in Melbourne, Australia demonstrated that the antithrombotic effect is comparable to the clinically used conformation-unspecific GPIIb/GPIIIa blockers tirofiban and eptifibatide. However, in clear contrast to these blockers, Affimed's antibody did not prolong bleeding times. This antibody thus represents a novel future approach for antiplatelet therapy.
 
Original publication: Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, et al.; "Conformation-specific blockade of the integrin GPIIb/IIIa: A novel antiplatelet strategy that selectively targets activated platelets"; Circ Res. 2006; 99:25-33.